Press Release:

CardioWest patient Hans Walter Thrun doing yardwork with the European portable driver.

TUCSON, Ariz. – July 25, 2007 – Although the CardioWest™ temporary Total Artificial Heart (TAH-t) was designed, engineered and is privately owned and manufactured in the United States, it is the Europeans who are being discharged to recover at home while Americans with the TAH-t are confined to the hospital. These patients are waiting for donor hearts for transplant.

Since the start of the 2003 clinical study of the portable driver, stable patients in Europe have been discharged to recover at home. The driver provides precisely calibrated pulses of air that power the TAH-t. The portable driver received the CE mark for use throughout Europe on July 17, 2006.

“We can describe the quality of life of patients supported by the portable driver as near normal. They are very active. They can go shopping, drive in cars, they can go for holidays, for vacations and so on. Recovery at home eliminates hospitalization costs for this part of their care,” said Dr. Aly El-Banayosy, who pioneered the clinical study of the portable driver at the Heart and Diabetes Center NRW in Bad Oeynhausen, Germany.

CardioWest patient Hans Walter Thrun was able to recover at home while he waited for a donor heart because of the CE approved portable driver.

“The best part of the portable driver is that I can live free, free from the hospital, free from the doctors,” said TAH-t patient Hans Walter Thrun, who lives a two hour drive away from Bad Oeynhausen. “I can live in my own four walls, and I can live with my wife, with my friends, with my children and my mother and everyone. I can live a normal life, and I think that’s the best part of the artificial heart and the combination of this portable driver.”

Thrun received his CardioWest TAH-t on May 18, 2006. Exactly one year later, he was successfully transplanted with a human heart on May 18, 2007. He was interviewed at his home in the small town of Ennepetal, Germany on Nov. 18, 2006.

The artificial heart works exceptionally well on both continents. In the pivotal clinical study, the TAH-t had a bridge-to-transplant success rate of 79 percent (New England Journal of Medicine 2004; 351: 859-867). This is the highest success rate of any heart assist device in the world.

The only FDA approved driver available for use with the TAH-t in the U.S. is “Big Blue.” This 400 pound driver requires patients to be hospitalized until transplant.

SynCardia Systems, Inc., manufacturer of the CardioWest TAH-t, has taken preliminary steps towards addressing the need for a portable driver in the U.S. and is working with the FDA to move forward in this direction.

###

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 250 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

SynCardia Ranked #20 Among World's 50 Most Innovative Companies
In March 2011, Fast Company magazine ranked SynCardia #20 in its annual list of the "World's 50 Most Innovative Companies" for "giving mobility to artificial heart recipients." Weighing 13.5 pounds, SynCardia's Freedom® portable driver is the world's first wearable driver designed to power the Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn

Media Contact:
Don Isaacs
Vice President of Communications
SynCardia Systems, Inc.
Cell: (520) 955-0660